Summary
UCLA researchers in the Departments of Neurology have developed a novel treatment for Lysosomal-storage diseases (LSDs) with neurological impairment.
Background
Lysosomal-storage diseases (LSDs) cause abnormal accumulation and aggregation of proteins due to insufficient clearance of proteins by the lysosomes. Although individually rare, LSDs as a group occur in at least 1/7700 live births. However, to date, there are no approved products for the treatment of LSDs with neurologic impairment. Therefore, there is an urgent need for improved treatments for LSDs with neurological impairment.
Current therapies for LSDs, such as enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT) and experimental gene therapy, are some of the most expensive in medicine. Moreover, the neurological degradation accompanied by multiple complications requires a multidisciplinary management to allow adapted symptomatic treatment.
Innovation
Professor Bitan and coworkers have demonstrated that molecular tweezer, such as CLR01, covered by UCLA case 2008-489, are capable of improving memory deficits, attenuating neuronal loss, and reducing inflammation in LSDs, thus providing a novel treatment for LSDs with neurological impairment. Molecular tweezers are demonstrated to both prevent the formation of amyloid deposits and reduce the existing deposits in LSD mice. In addition, the treatment led to improvement of neuroinflammation in the brain, as both microgliosis and astrocytosis were reduced significantly following the treatment.
Applications
▶ Treatment of Mucopolysaccharidosis type III (MPS III)
▶ Treatment of other lysosomal-storage diseases (LSDs), such as Krabbe disease, metachromatic leukodystrophy, Batten disease, Sandhoff disease, Niemann-Pick disease
Advantages
▶ No previous therapeutic approaches
▶ Non-cytotoxic
▶ Efficacious for both therapeutics and prevention
▶ Improved neuroinflammation in the brain